Your browser is no longer supported. Please, upgrade your browser.
Settings
TSRO Tesaro, Inc. daily Stock Chart
TSRO [NASD]
Tesaro, Inc.
Index- P/E- EPS (ttm)-9.94 Insider Own0.20% Shs Outstand53.29M Perf Week-0.20%
Market Cap6.31B Forward P/E- EPS next Y-5.46 Insider Trans-24.42% Shs Float52.48M Perf Month8.61%
Income-526.90M PEG- EPS next Q-0.96 Inst Own- Short Float18.46% Perf Quarter-17.15%
Sales40.50M P/S155.84 EPS this Y-27.40% Inst Trans0.71% Short Ratio8.27 Perf Half Y-22.10%
Book/sh7.41 P/B15.98 EPS next Y37.90% ROA-71.70% Target Price169.50 Perf Year13.76%
Cash/sh9.53 P/C12.43 EPS next 5Y24.80% ROE-103.10% 52W Range96.52 - 192.94 Perf YTD-11.93%
Dividend- P/FCF- EPS past 5Y-67.60% ROI-49.00% 52W High-39.78% Beta1.59
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin76.80% 52W Low20.38% ATR5.29
Employees446 Current Ratio5.70 Sales Q/Q-17.60% Oper. Margin- RSI (14)40.69 Volatility3.32% 4.32%
OptionableYes Debt/Eq0.34 EPS Q/Q-118.10% Profit Margin- Rel Volume0.60 Prev Close118.44
ShortableYes LT Debt/Eq0.34 EarningsAug 08 AMC Payout- Avg Volume1.17M Price116.19
Recom2.00 SMA20-5.64% SMA50-5.97% SMA200-19.17% Volume178,223 Change-1.90%
Aug-17-17Initiated Evercore ISI In-line $121
Jul-07-17Initiated Gabelli & Co Buy $175
Jun-05-17Reiterated FBR & Co. Mkt Perform $200 → $195
May-10-17Reiterated FBR & Co. Mkt Perform $202 → $200
Apr-12-17Initiated Piper Jaffray Overweight $180
Apr-10-17Initiated Janney Neutral $141
Mar-28-17Reiterated FBR & Co. Mkt Perform $200 → $202
Mar-15-17Reiterated Wedbush Outperform $200 → $164
Feb-27-17Downgrade Robert W. Baird Outperform → Neutral $127 → $182
Feb-17-17Reiterated RBC Capital Mkts Outperform $142 → $202
Feb-16-17Downgrade FBR & Co. Outperform → Mkt Perform $151 → $202
Feb-10-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-13-17Initiated Morgan Stanley Overweight
Dec-27-16Reiterated FBR & Co. Outperform $133 → $151
Nov-07-16Reiterated Lake Street Buy $114 → $150
Nov-04-16Reiterated FBR & Co. Outperform $115 → $133
Nov-04-16Downgrade Raymond James Outperform → Mkt Perform
Oct-10-16Upgrade BofA/Merrill Neutral → Buy
Oct-10-16Reiterated Wedbush Outperform $107 → $139
Oct-10-16Reiterated RBC Capital Mkts Outperform $122 → $128
Sep-18-17 10:01AM  TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion Zacks
07:30AM  Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaros Ovarian Cancer Drug ACCESSWIRE
Sep-15-17 08:38AM  TESARO Receives Positive CHMP Opinion for ZEJULA® GlobeNewswire
07:45AM  TESARO Receives Positive CHMP Opinion for ZEJULA® GlobeNewswire
Sep-12-17 01:38AM  ETFs with exposure to TESARO, Inc. : September 12, 2017 Capital Cube
Sep-11-17 08:01AM  TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting GlobeNewswire
Sep-06-17 08:06AM  See what the IHS Markit Score report has to say about TESARO Inc. Markit
Sep-05-17 08:06AM  See what the IHS Markit Score report has to say about TESARO Inc. Markit
Sep-01-17 10:07AM  TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 1, 2017 Capital Cube
Aug-31-17 09:44PM  ETFs with exposure to TESARO, Inc. : September 1, 2017 Capital Cube
Aug-28-17 07:45PM  We Got It Wrong With OPKO Health -- Now What? Motley Fool
Aug-25-17 08:04AM  See what the IHS Markit Score report has to say about TESARO Inc. Markit
08:02AM  TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting GlobeNewswire
Aug-24-17 11:34AM  TESARO, Inc. :TSRO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 04:15PM  TESARO Announces Participation at Four Investor Conferences GlobeNewswire
Aug-18-17 06:33PM  Tesaro: Losing Its Edge? Barrons.com
04:27PM  Ovarian Cancer Market Still Up For Grabs Barrons.com
07:00AM  Featured Company News - Moleculin Biotech Acquires Active Drug Compound for the Treatment of Brain Cancer ACCESSWIRE
Aug-16-17 08:05AM  See what the IHS Markit Score report has to say about TESARO Inc. Markit
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about TESARO Inc. Markit
Aug-13-17 08:21PM  Edited Transcript of TSRO earnings conference call or presentation 8-Aug-17 8:15pm GMT Thomson Reuters StreetEvents
Aug-09-17 09:02AM  Biotech: Why Clovis And Tesaro Look Well Positioned Barrons.com -6.54%
Aug-08-17 05:07PM  Tesaro reports 2Q loss Associated Press
04:05PM  TESARO Announces Second-Quarter 2017 Operating Results GlobeNewswire
02:36PM  A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision Benzinga
10:00AM  Investor Network: TESARO, Inc. to Host Earnings Call ACCESSWIRE
Aug-04-17 08:51AM  Why Earnings Season Could Be Great for TESARO (TSRO) Zacks
Jul-27-17 09:25AM  Waltham's Tesaro grabs $100M in cancer drug partnership with Takeda American City Business Journals
07:02AM  TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan GlobeNewswire
Jul-25-17 04:15PM  TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
01:46PM  ETFs with exposure to TESARO, Inc. : July 25, 2017 Capital Cube
Jul-14-17 05:15PM  ETFs with exposure to TESARO, Inc. : July 14, 2017 Capital Cube
Jul-13-17 04:57PM  Why National Beverage, Tesaro, and Community Health Systems Slumped Today Motley Fool -6.66%
01:11PM  TESARO Inc (TSRO) Shares Fall as Company Struggles to Find Buyer InvestorPlace
11:28AM  Tesaro May Beat, But It's Not A Buy, Says Janney Barrons.com
10:34AM  Sale process for biotech Tesaro seen unlikely to result in deal CNBC
Jul-11-17 09:01AM  Is the Options Market Predicting a Spike in TESARO, Inc. (TSRO) Stock? Zacks
Jul-07-17 10:45AM  Tesaro: Why Gabelli Sees 20%+ Upside Barrons.com
Jun-29-17 09:00AM  TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference GlobeNewswire
Jun-28-17 09:07AM  TESARO, Inc. breached its 50 day moving average in a Bearish Manner : TSRO-US : June 28, 2017 Capital Cube
09:00AM  TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England GlobeNewswire
Jun-26-17 04:26PM  How Things Look for Opko Health, Inc. in 3 Charts Motley Fool
04:15PM  TESARO Joins Healthcare Businesswomens Association as Corporate Partner GlobeNewswire
Jun-20-17 04:15PM  Could Tesaro Overcome Clovis' Lead On Combos With Merck & Co.? Investor's Business Daily
12:21PM  Biotech ETFs: Still Riding High Barrons.com
11:10AM  Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study Zacks
Jun-19-17 05:28PM  Here's what's behind the biotech breakout CNBC Videos
04:38PM  Biotech Flew Nearly 50% On Strong Trial But Is Its Drug Better? Investor's Business Daily
02:21PM  Clovis Oncology's Rubraca Notches Key Trial Win Motley Fool
02:18PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
12:37PM  Tesaro: Is The Selloff Overdone? Barrons.com
11:48AM  Why Cancer Biotech Clovis Oncologys Stock Is Soaring Fortune
11:45AM  Why Tesaro Inc. Stock Briefly Dipped Today Motley Fool
11:00AM  Why Clovis Oncology Stock Is Soaring Today Motley Fool
Jun-18-17 07:01PM  New test may turn AZ's Lynparza into precision drug for prostate cancer Reuters
Jun-17-17 06:42AM  3 Biotech Stocks That Could Become M&A Targets Motley Fool
Jun-16-17 04:41PM  Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs? Investor's Business Daily
Jun-15-17 03:34PM  ETFs with exposure to TESARO, Inc. : June 15, 2017 Capital Cube
Jun-14-17 08:21AM  TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : June 14, 2017 Capital Cube
Jun-13-17 05:07PM  Will Tesaro Be the Focus of the Next Biotech Bidding War? Motley Fool
08:00AM  Today's Research Reports on Stocks to Watch: Gilead Sciences and Tesaro Accesswire
Jun-09-17 01:00PM  Tesaro: What the Heck Just Happened? Barrons.com
12:35PM  Tesaro stock dips 10% on probably a nothing burger MarketWatch
Jun-07-17 04:30PM  TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
Jun-06-17 08:15AM  Corporate News Blog - Puma Biotech Announced Positive Results from PB272 Phase-II Data at the ASCO, 2017 Accesswire
06:30AM  Bluebird and Radius gain, while Blueprint and Tesaro fall, at ASCO cancer summit American City Business Journals
Jun-05-17 02:52PM  ETFs with exposure to TESARO, Inc. : June 5, 2017 Capital Cube -5.71%
01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
12:49PM  Tesaro: What's Tearing At The Stock? Barrons.com
Jun-03-17 06:30PM  TESARO Provides Business and Pipeline Update at ASCO Investor Briefing GlobeNewswire
Jun-02-17 10:00AM  TESARO, Inc. :TSRO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 08:20AM  TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : June 1, 2017 Capital Cube
06:55AM  Tesaro shares jump on report the cancer drug firm is eyeing a sale American City Business Journals
May-31-17 05:59PM  "Fast Money" final trades: QCOM, PANW & more CNBC Videos
05:23PM  Tesaro Spikes On Rumors It's Seeking A Takeover Investor's Business Daily
06:00AM  Biotech Musical Chairs: Who Leads Next Investopedia
May-25-17 04:15PM  Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-22-17 09:01AM  National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community GlobeNewswire
May-18-17 03:44PM  Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments Investor's Business Daily +6.76%
02:20PM  TESARO, Inc. Value Analysis (NASDAQ:TSRO) : May 18, 2017 Capital Cube
10:18AM  Industry News And Stocks To Watch Investor's Business Daily
May-17-17 05:05PM  Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug? Investor's Business Daily
08:07AM  TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : May 17, 2017 Capital Cube
May-16-17 05:11AM  Edited Transcript of TSRO earnings conference call or presentation 9-May-17 8:15pm GMT Thomson Reuters StreetEvents
May-11-17 02:01AM  TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer GlobeNewswire
May-10-17 09:35PM  Edited Transcript of TSRO earnings conference call or presentation 9-May-17 8:15pm GMT Thomson Reuters StreetEvents
May-09-17 04:44PM  Tesaro reports 1Q loss Associated Press
04:05PM  TESARO Announces First-Quarter 2017 Operating Results GlobeNewswire
10:15AM  Investor Network: TESARO, Inc. to Host Earnings Call Accesswire
May-08-17 01:29PM  KITE Plunges, Take Sector With It Investopedia -5.69%
May-01-17 08:51AM  Neurocrine Biosciences new drug may cost patients more than $10,000 a month, twice as much as expected MarketWatch
08:30AM  TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA GlobeNewswire
Apr-27-17 12:55PM  Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space Benzinga
08:15AM  TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 GlobeNewswire
Apr-26-17 08:31AM  TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission GlobeNewswire
Apr-25-17 04:15PM  TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
04:15PM  Tesaro Announces Participation in Two Investor Conferences GlobeNewswire
03:43PM  Tesaro Inc Bulls Need a Reality Check Motley Fool
Apr-24-17 06:00AM  Biotech M&A Plunges as Trump Attacks Drug Companies Investopedia
Apr-21-17 07:21AM  Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing Motley Fool
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. The company is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in pre-clinical research stage targeting lymphocyte-activation gene-3. It has license and collaboration agreements with AnaptysBio, Inc.; and The University of Texas MD Anderson Cancer Center, as well as with Janssen Biotech, Inc., Zai Lab (Shanghai) Co., Ltd, and OPKO Health, Inc. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
English Edward CVP of Finance & AdministrationSep 06Option Exercise38.4210,862417,29311,258Sep 06 09:00 PM
English Edward CVP of Finance & AdministrationSep 06Sale134.9210,8621,465,458396Sep 06 09:00 PM
Oliveira OrlandoSVP & GM, InternationalSep 05Sale132.66719,4196,555Sep 06 09:13 PM
Bogle Grant C.Sr. VP, Chief Commercial Ofc.Sep 01Option Exercise55.4811,250624,13214,460Sep 06 09:12 PM
Oliveira OrlandoSVP & GM, InternationalSep 01Option Exercise0.001,25006,626Sep 06 09:13 PM
Bogle Grant C.Sr. VP, Chief Commercial Ofc.Sep 01Sale135.0014,1671,912,545293Sep 06 09:12 PM
Farmer Joseph LSr.VP, Gen.Counsel & SecretaryAug 01Option Exercise0.0062504,616Aug 03 05:13 PM
English Edward CVP of Finance & AdministrationJun 06Option Exercise28.128,500238,9908,896Jun 08 05:18 PM
English Edward CVP of Finance & AdministrationJun 06Sale138.658,5001,178,520396Jun 08 05:18 PM
Huber Martin H. Jr.SVP & Cheif Medical OfficerApr 03Sale153.02829126,8545,693Apr 04 06:16 PM
English Edward CV.P. of Finance & Admin.Mar 06Option Exercise28.9610,000289,60010,396Mar 08 05:17 PM
English Edward CV.P. of Finance & Admin.Mar 06Sale178.0610,0001,780,600396Mar 08 05:17 PM
English Edward CVP of Finance & AdministrationMar 02Sale177.6122940,673396Mar 03 05:15 PM
Bogle Grant C.Sr VP,Chief Commercial OfficerMar 02Sale177.611,447257,0023,155Mar 03 05:15 PM
Hedley Mary LynnePresident & COOMar 02Sale177.613,927697,4746,073Mar 03 05:16 PM
Farmer Joseph LSr VP,Gen. Counsel & SecretaryMar 02Sale177.611,449257,3573,819Mar 03 05:16 PM
Oliveira OrlandoSVP & GM, InternationalMar 02Sale177.6124944,2255,376Mar 03 05:18 PM
Huber Martin H. Jr.Sr. VP, Chief Medical OfficerMar 02Sale177.611,428253,6274,772Mar 03 05:17 PM
PEARSON TIMOTHY RExec. VP, CFOMar 02Sale177.611,447257,0022,928Mar 03 05:19 PM
PEARSON TIMOTHY RExec. VP, CFOMar 01Option Exercise0.004,37504,375Mar 03 05:19 PM
Huber Martin H. Jr.Sr. VP, Chief Medical OfficerMar 01Option Exercise0.004,37506,200Mar 03 05:17 PM
MOULDER LEON O JRChief Executive OfficerMar 01Option Exercise0.0012,50001,018,828Mar 03 05:18 PM
Oliveira OrlandoSVP & GM, InternationalMar 01Option Exercise0.004,37505,625Mar 03 05:18 PM
Farmer Joseph LSr VP,Gen. Counsel & SecretaryMar 01Option Exercise0.004,37505,268Mar 03 05:16 PM
Hedley Mary LynnePresident & COOMar 01Option Exercise0.0010,000010,000Mar 03 05:16 PM
Bogle Grant C.Sr VP,Chief Commercial OfficerMar 01Option Exercise0.004,37504,602Mar 03 05:15 PM
English Edward CVP of Finance & AdministrationMar 01Option Exercise0.006250625Mar 03 05:15 PM
English Edward CVP of Finance and Admin.Dec 12Option Exercise29.3810,000293,80010,000Dec 14 04:17 PM
English Edward CVP of Finance and Admin.Dec 12Sale129.0510,0001,290,4700Dec 14 04:17 PM
Huber Martin H. Jr.SVP & Chief Medical OfficerNov 02Sale121.2932739,6621,515Nov 03 06:27 PM
Huber Martin H. Jr.SVP & Chief Medical OfficerSep 22Sale108.1240844,113842Sep 23 08:50 PM